Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 82 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Desc)]
Φίλτρα: Συντάκτης is Pectasides, Dimitrios  [Clear All Filters]
2013
Fountzilas, E., Kotoula V., Angouridakis N., Karasmanis I., Wirtz R. M., Eleftheraki A. G., et al. (2013).  Identification and validation of a multigene predictor of recurrence in primary laryngeal cancer.. PLoS One. 8(8), e70429.
Fountzilas, G., Kotoula V., Pectasides D., Kouvatseas G., Timotheadou E., Bobos M., et al. (2013).  Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.. PLoS One. 8(7), e69256.
Stavropoulou, A. V., Fostira F., Pertesi M., Tsitlaidou M., Voutsinas G. E., Triantafyllidou O., et al. (2013).  Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.. PLoS One. 8(3), e58182.
Strimpakos, A., Pentheroudakis G., Kotoula V., De Roock W., Kouvatseas G., Papakostas P., et al. (2013).  The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.. Clin Colorectal Cancer. 12(4), 267-274.e2.
Pentheroudakis, G., Kotoula V., Eleftheraki A. G., Tsolaki E., Wirtz R. M., Kalogeras K. T., et al. (2013).  Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).. PLoS One. 8(7), e70634.
2014
Koletsa, T., Stavridi F., Bobos M., Kostopoulos I., Kotoula V., Eleftheraki A. G., et al. (2014).  alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies.. BMC Clin Pathol. 14, 28.
Pentheroudakis, G., Kotoula V., Kouvatseas G., Charalambous E., Dionysopoulos D., Zagouri F., et al. (2014).  Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.. Clin Breast Cancer. 14(5), 330-8.
Papatheodoridis, G., Goulis J., Manolakopoulos S., Margariti A., Exarchos X., Kokkonis G., et al. (2014).  Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy.. J Hepatol. 60(1), 62-8.
Karavasilis, V., Kosmidis P., Syrigos K. N., Mavropoulou P., Dimopoulos M. A., Kotoula V., et al. (2014).  Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.. Anticancer Res. 34(10), 5649-55.
Fountzilas, G., Dafni U., Papadimitriou C., Timotheadou E., Gogas H., Eleftheraki A. G., et al. (2014).  Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.. BMC Cancer. 14, 515.
Razis, E., Pentheroudakis G., Rigakos G., Bobos M., Kouvatseas G., Tzaida O., et al. (2014).  EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.. J Cancer Res Clin Oncol. 140(5), 737-48.
Purrington, K. S., Slager S., Eccles D., Yannoukakos D., Fasching P. A., Miron P., et al. (2014).  Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.. Carcinogenesis. 35(5), 1012-9.
Vassilakopoulou, M., Togun T., Dafni U., Cheng H., Bordeaux J., Neumeister V. M., et al. (2014).  In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.. PLoS One. 9(6), e99131.
2015
Koutras, A., Kalogeras K. T., Wirtz R. M., Alexopoulou Z., Bobos M., Zagouri F., et al. (2015).  Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.. J Transl Med. 13, 171.
Pentheroudakis, G., Raptou G., Kotoula V., Wirtz R. M., Vrettou E., Karavasilis V., et al. (2015).  Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial.. PLoS One. 10(5), e0124612.
Kourea, H. P., Kotoula V., Koutras A., Alexopoulou Z., Papaspirou I., Skarlos D. V., et al. (2015).  Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study.. Histol Histopathol. 30(9), 1129-41.
Pavlakis, K., Bobos M., Batistatou A., Kotoula V., Eleftheraki A. G., Stofas A., et al. (2015).  p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.. Pathol Oncol Res. 21(2), 273-82.
Koumarianou, A., Karayannopoulou G., Gourgioti G., Batistatou A., Bobos M., Efstratiou I., et al. (2015).  PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.. Cancer Chemother Pharmacol. 75(6), 1289-301.
Pectasides, D., Karavasilis V., Papaxoinis G., Gourgioti G., Makatsoris T., Raptou G., et al. (2015).  Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or. BMC Cancer. 15, 384.
Papaxoinis, G., Kotoula V., Alexopoulou Z., Kalogeras K. T., Zagouri F., Timotheadou E., et al. (2015).  Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.. PLoS One. 10(10), e0140293.
Koutsoukos, K., Tzannis K., Christodoulou C., Karavasilis V., Bakoyiannis C., Makatsoris T., et al. (2015).  Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG).. World J Urol.
2016
Stavridi, F., Kalogeras K. T., Pliarchopoulou K., Wirtz R. M., Alexopoulou Z., Zagouri F., et al. (2016).  Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.. PLoS One. 11(10), e0164013.
Fountzilas, E., Kotoula V., Zagouri F., Giannoulatou E., Kouvatseas G., Pentheroudakis G., et al. (2016).  Disease evolution and heterogeneity in bilateral breast cancer.. Am J Cancer Res. 6(11), 2611-2630.
Kotoula, V., Karavasilis V., Zagouri F., Kouvatseas G., Giannoulatou E., Gogas H., et al. (2016).  Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.. Breast Cancer Res Treat. 158(2), 307-21.
Cohen, S. A., Wu C., Yu M., Gourgioti G., Wirtz R., Raptou G., et al. (2016).  Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.. Clin Colorectal Cancer. 15(2), 164-9.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές